晚期鼻咽癌诱导化疗+同步放化疗与诱导化疗+放疗疗效比较

摘要

目的 比较诱导化疗+同步放化疗与诱导化疗+放疗在T3～4N0～1M0和T1～4N2～3M0期鼻咽癌患者的疗效.方法 对2002-2005年间收治的92分期为Ⅲ、Ⅳa期的400例鼻咽癌患者随机分为诱导化疗+同步放化疗组和诱导化疗+放疗组,其中对T3～4N0～1M0(197例)和T1～4N2～3M0(203例)期分别进行亚组分析.放疗采用常规分割方案,化疗采用氟尿嘧啶脱氧核苷+卡铂.结果 中位随访3.9年,随访率96.2%.T3～4N0～1M0期鼻咽癌患者诱导化疗+同步放化疗组(104例)和诱导化疗+放疗组(93例)的3年总生存率、无瘤生存率、无局部区域复发生存率、无远处转移生存率分别为84.0%和85.9%(χ2=0.08,P=0.780)、77.0%和72.0%(χ2=0.44,P=0.510)、89.5%和92.3%(χ2=0.65,P=0.420)、84.9%和77.0%(χ2=1.59,P=0.210);T1～4 N2～3 M0期(97例和106例)的分别为67.4%和82.2%(χ2=3.48,P=0.060)、61.5%和68.0%(χ2=1.86,P=0.170)、86.2%和87.0%(χ2=0.57,P=0.450)、66.2%和75.6%(χ2=2.07,P=0.150).急性毒副反应只有白细胞减少诱导化疗+同步放化疗比诱导化疗+放疗严重,其余相似.结论 采用诱导化疗+同步放化疗方案未能较诱导化疗+放疗进一步提高T3～4N0～1M0、T1～4N2～3M0期鼻咽癌总生存率.%Objective To compare the efficacy of concurrent chemoradiotherapy versus radiotherapy alone for T3-4 N0-1 M0 and T14 N2-3 M0 nasopharyngeal carcinoma (NPC) after induction chemotherapy.Methods From 2002 to 2005,400 patients with stage Ⅲ and Ⅳa NPC were randomly divided into 2 groups :induction chemotherapy followed by concurrent chemoradiotherapy group (IC/CCRT,201 patients),and induction chemotherapy followed by radiotherapy alone group (IC/RT, 199 patients).Subgroup analysis was conducted for 197 patients with stage T3-4N0-1M0 NPC and 203 with stage T1-4N2-3M0 NPC.Results The follow-up rate were 96.2%, with a median followg-up time of 3.9 years.For T3-4N0-1 M0 NPC patients in IC/CCRT group (104 patients) and IC/RT group (93 patients), the 3-year overall survival, disease-free survival, locoregional recurrence-free survival and distant metastasis-free survival rates were 84.0% and 85.9% (χ2=0.08,P =0.780) ,77.0% and 72.0% (χ2=0.44,P =0.510) ,89.5% and 92.3% (χ2=0.65 ,P = 0.420), and 84.9% and 77.0% (χ2= 1.59, P = 0.210), respectively; For T1-4 N2-3 M0 NPC patients in IC/CCRT group (97 patients) and IC/RT group (106 patients), the corresponding rates were 67.4% and 82.2% (χ2=3.48,P=0.060), 61.5% and 68.0% (χ2= 1.86,P=0.170), 86.2% and 87.0% (χ2=0.57 ,P =0.450) and 66.2% and 75.6% (χ2=2.07 ,P =0.150), respectively.Acute sideeffects were similar except more leucocytopenia in IC/CCRT group than IC/RT group.Conclusions Compared with IC/RT, IC/CCRT dose not improve the overall survival in patients with T3-4N0-1 M0 and T1-4 N2-3 M0 NPC.